



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

29.06.2021

To,  
Corporate Services Department,  
BSE Ltd.,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai- 400001

Dear Sir,

**Sub: Outcome Of Board Meeting For The Approval of Audited Financial Results For The Fourth Quarter And Year Ended 31<sup>st</sup> March, 2021 And Recommendation Of Dividend**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Tuesday 29<sup>th</sup> June, 2021, at 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034**, have inter-alia approved the Standalone and Consolidated Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2021.

In terms of the Provisions of Regulation 33 and 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Audited Standalone financial results of the Company for the quarter and year ended 31<sup>st</sup> March, 2021 along with the Audit Report on the standalone financial statements.
2. Audited Consolidated financial results of the Company for the quarter and year ended 31<sup>st</sup> March, 2021 along with the Audit Report on the consolidated financial statements.
3. The disclosures under Regulation 52(4) of the Listing Regulations forms part of the standalone financial results of the Company for the year ended 31<sup>st</sup> March, 2021.
4. Declaration that the statutory auditors have Issued audit reports with unmodified opinion on financial statements.

**R.O. & Works:** Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan  
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan  
**E-mail:** [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)  
**Website:** [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

Further, the Board of Directors have recommended a dividend of Rs. 1.50/- (Rupees One Fifty Paise Only) per equity share for the Financial Year ended on 31<sup>st</sup> March, 2021. The said dividend, if declared at the ensuing Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws.

The meeting of Board of Directors commenced at 04:00 P.M. and concluded at 05:20 P.M.

The above information will be available on the website of the company i.e <https://titanbiotechltd.com> and BSE Ltd i.e [www.bseindia.com](http://www.bseindia.com) .

Request to kindly take this information on record and acknowledge.

Thanking you,  
Yours faithfully,  
For Titan Biotech Limited

Charanjit Singh  
Company Secretary  
Membership Number: A12726

Encl. as above

**R.O. & Works:** Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan  
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan  
**E-mail:** [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)  
**Website:** [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,  
Corporate Services Department,  
BSE Ltd.,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai- 400001

Date: 29/06/2021

Dear Ma'am/Sir,

**Scrip Code: 524717**

**Sub: Declaration Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for Unmodified Opinion**

I, Prem Shankar Gupta, Chief Financial Officer of Titan Biotech Limited hereby confirm and declare that the Statutory Auditors of the Company, M/s Sunita Agrawal & Co., Chartered Accountants (Firm Registration No. 515225C), have not expressed any modified opinion in their Audit Report pertaining to Annual Audited Financial Results (Standalone & Consolidated) of the Company for the financial year ended 31<sup>st</sup> March, 2021.

This declaration is given in compliance with Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May, 27, 2016 and SEBI vide Notification No. SEBI/LAD-NRO/GN/2016-17 /001 dated May 25, 2016.

Kindly take the above in your record.

**For and on behalf of  
Titan Biotech Limited**



**Prem Shankar Gupta  
Chief Financial Officer**





# Sunita Agrawal & Co.

(Chartered Accountants)

Independent Auditor's Report on the quarterly and year to date Audited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of TITAN BIOTECH LIMITED

Report on the audit of the Standalone Ind AS Financial Results

## Opinion

We have audited the accompanying Statement of quarterly and year to date standalone Financial Results of **TITAN BIOTECH LIMITED** ("the Company") for the quarter ended 31<sup>st</sup> March, 2021 and for the year ended 31<sup>st</sup> March, 2021 (the Statement), attached herewith being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- is presented in accordance with the requirements of the Listing Regulations in this Regard; and
- gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the company for the quarter ended March 31, 2021 and for the year ended on March 31, 2021.

## Basis for Opinion

We conducted our audit of the Statement in accordance with the Standard on Auditing (SAs) specified under Section 143 (10) of the Companies Act, 2013, as amended ("The Act"). Our responsibilities under those Standards are further described in the Auditors Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

## Emphasis of Matter : Covid 19

We draw your attention to Note no. 5 of the Statement which explains the management assessment of the financial impact due to lockdown restrictions related to Covid 19 pandemic imposed by the Government for which a definitive assessment of the impact is dependent upon future economic conditions. Our Opinion is not modified in respect of this matter.



Head Office : 10, Giriraj Nagar, Inside Fort, Bharatpur (Rajasthan)-321001, Ph. : 05644-225679, M : 9899567391  
Branch Office : A-160, Boulevard, Hotel Crowne Plaza, Mayur Vihar, Phase-1, Delhi-110091, Ph. : 011-49868379

E-mail : sunitaca\_97@yahoo.com | sac.ica@gmail.com | info@taxfirst.in

Web : www.consultants.tax, www.taxfirst.in

### **Management's Responsibilities for the Standalone Ind AS Financial Results**

The Statement has been prepared on the basis of the standalone annual financial statements. The board of directors of the company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The Board of Director are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Ind AS Financial Results**

Our objectives are to obtain other reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.





- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143 (3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or if such disclosures are in, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and where applicable related safeguards.

#### Other Matter

The Statement includes the results for the quarter ended March 31, 2021 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2021 and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For Sunita Agrawal & Co  
Chartered Accountants  
FRN: 515225C  
  
(CA Sunita Agrawal)  
FCA Partner  
M.No.095196  
UDIN: 21095196AAAAKI1092

Place: Delhi

Date : 29<sup>th</sup> June, 2021



# Sunita Agrawal & Co.

(Chartered Accountants)

Independent Auditor's Report on the quarterly and year to date Audited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of TITAN BIOTECH LIMITED

Report on the audit of the Consolidated Ind AS Financial Results

## Opinion

We have audited the accompanying Statement of quarterly and year to date consolidated Financial Results of **TITAN BIOTECH LIMITED** ("Holding Company") and its subsidiary Peptech Biosciences Limited (together referred to as "the Group") for the quarter ended 31<sup>st</sup> March, 2021 and for the year ended 31<sup>st</sup> March, 2021 (the Statement), attached herewith being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

i. includes the results of the following entities:-

a. Subsidiary Company: Peptech Biosciences Limited

ii. is presented in accordance with the requirements of the Listing Regulations in this Regard; and

iii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the company for the quarter ended March 31, 2021 and for the year ended on March 31, 2021.

## Basis for Opinion

We conducted our audit of the Statement in accordance with the Standard on Auditing (SAs) specified under Section 143 (10) of the Companies Act, 2013, as amended ("The Act"). Our responsibilities under those Standards are further described in the Auditors Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. In case of Subsidiary company we rely on other auditors report. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

## Emphasis of Matter : Covid 19

We draw your attention to Note no. 5 of the Statement which explains the management assessment of the financial impact due to lockdown restrictions related to Covid 19 pandemic imposed by the Government for which a definitive assessment of the impact



Head Office : 10, Giriraj Nagar, Inside Fort, Bharatpur (Rajasthan)-321001, Ph. : 05644-225679, M : 9899567391

Branch Office : A-160, Boulevard, Hotel Crowne Plaza, Mayur Vihar, Phase-1, Delhi-110091, Ph. : 011-49868379

E-mail : sunitaca\_97@yahoo.com | sac.ica@gmail.com | info@taxfirst.in

Web : www.consultants.tax, www.taxfirst.in



dependent upon future economic conditions. Our Opinion is not modified in respect of this matter.

#### **Management's Responsibilities for the Consolidated Ind AS Financial Results**

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding company's board of directors are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Group including its associates and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and its associates are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company as aforesaid.

In preparing the statement, the respective Board of Directors of the Companies included in the Group are responsible for assessing the ability of the Group and its associates to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group and of its associates are also responsible for overseeing the financial reporting process of the Group and its associates.

#### **Auditor's Responsibilities for the Audit of the Consolidated Ind AS Financial Results**

Our objectives are to obtain other reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:





- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143 (3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or if such disclosures are in, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group and its associates of which we are the independent auditors and whose financial information we have audited to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of Holding Company and such other entities included in the Statement of which we are independent auditors, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and where applicable related safeguards.



**Other Matter**

The Statement includes the results for the quarter ended March 31, 2021 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2021 and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.



For Sunita Agrawal & Co

Chartered Accountants

FRN: 515225C

(Sunita Agrawal)

FCA Partner

M.No.095196

UDIN: 21095196AAAAKK8131

Place: Delhi

Date : 29<sup>th</sup> June, 2021



**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2021**

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE				
		QUARTER ENDED			YEAR ENDED	
		31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
		AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED
1	<b>INCOME</b>					
	Revenue from operations	2,941.33	3,097.10	1,800.55	12,245.94	6,947.63
	Other Income	20.03	13.53	21.00	65.99	40.95
	<b>Total Income</b>	<b>2,961.36</b>	<b>3,110.63</b>	<b>1,821.55</b>	<b>12,311.93</b>	<b>6,988.58</b>
2	<b>EXPENSES</b>					
	Cost of Materials Consumed	1,584.60	1,379.38	860.52	5,554.05	3,675.32
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(69.27)	106.59	(20.43)	(222.63)	(65.44)
	Employee Benefit Expenses	367.12	305.87	292.11	1,204.36	1,002.60
	Finance Costs	39.56	25.87	48.15	127.54	190.09
	Depreciation and Amortization Expenses	77.27	44.55	43.30	210.41	174.52
	Other Expenses	438.56	392.68	365.07	1,529.61	1,248.65
	<b>Total Expenses</b>	<b>2,437.84</b>	<b>2,254.94</b>	<b>1,588.72</b>	<b>8,403.34</b>	<b>6,225.74</b>
3	Profit/(loss) before exceptional items and tax (1-2)	523.52	855.69	232.83	3,908.59	762.84
4	Exceptional Items	(41.45)	-	0.00	(32.44)	61.41
5	Profit/ (loss) before tax (3+4)	482.07	855.69	232.83	3,876.15	824.25
6	Tax expense:					
	I) Current Tax	148.18	208.87	44.97	984.75	184.84
	II) Deferred Tax	(4.23)	6.18	(5.39)	13.11	19.27
	(III) Earlier year taxes	-	(0.24)	-	1.02	-
	<b>Total Tax (I+II)</b>	<b>143.95</b>	<b>214.81</b>	<b>39.58</b>	<b>998.88</b>	<b>204.11</b>
7	Profit (Loss) for the period after Tax (5-6)	<b>338.12</b>	<b>640.88</b>	<b>193.25</b>	<b>2,877.27</b>	<b>620.14</b>
8	<b>Other comprehensive income (Net of Tax)</b>					
A.	Items that will not be reclassified to profit or loss					
	Re-measurement gain on defined benefit plans	6.04	-	(4.71)	6.04	(4.71)
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total Other Comprehensive Income for the period (A+B)(net of taxes)</b>	<b>6.04</b>	<b>-</b>	<b>(4.71)</b>	<b>6.04</b>	<b>(4.71)</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>344.16</b>	<b>640.88</b>	<b>188.54</b>	<b>2,883.31</b>	<b>615.43</b>
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37
11	Other Equity				5,755.64	2,954.96
12	Earnings per equity share (face value of Rs.10/- each) not annualised					
	(1) Basic	4.09	7.76	2.34	34.82	7.50
	(2) Diluted	4.09	7.76	2.34	34.82	7.50

**Notes:**

- The above audited standalone financial results for the quarter and year ended on 31.03.2021 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on June 29, 2021. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31st March 2021 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The COVID-19 outbreak and resulted national lockdown imposed by the Government of India has caused Pan-India disruption of business. The company has considered the possible risk that may result from the pandemic on the carrying amount of its financial and non-financial assets, for which the Company has used the principles of prudence in applying judgments and assumptions as well as the internal / external information available up to the date of approval of these results and the same does not have material impact on these financial results. The Company will continue to closely monitor any material impact of future economic conditions.
- The total sale for the quarter ended 31.03.2021 includes sale of Products of Rs. 548.34 Lakhs the demand for which arose due to Covid 19 Pandemic.**
- The standalone audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- During the year, the company paid Rs. 10.92 Lakhs towards corporate social responsibility (CSR) expenditure.
- The Board of Directors of the company has recommended a dividend of Rs. 1.50 per equity share for the financial year ended on 31st March, 2021. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.

For and on behalf of Board of Directors  
For TITAN BIOTECH LIMITED

**NARESH KUMAR SINGLA**  
Managing Director

Place : Delhi

Dated : 29.06.2021

DIN-00027448

**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2021**

(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE				
		QUARTER ENDED			YEAR ENDED	
		31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
		AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED
1	Total Income from Operations (Net)	2,961.36	3,110.63	1,821.55	12,311.93	6,988.58
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	523.52	855.69	232.83	3,908.59	762.84
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	482.07	855.69	232.83	3,876.15	824.25
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	338.12	640.88	193.25	2,877.27	620.14
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	344.16	640.88	188.54	2,883.31	615.43
6	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	5,755.64	2,954.96
8	Earning Per Share (of INR 10/- each)					
	(a) Basic	4.09	7.76	2.34	34.82	7.50
	(b) Diluted	4.09	7.76	2.34	34.82	7.50

**NOTES :**

- The above is an extract of the detailed format of standalone audited Financial Results for the quarter and year ended on 31.03.2021 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter and year ended on 31.03.2021 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above audited standalone financial results for the quarter and year ended on 31.03.2021 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on June 29, 2021. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31st March 2021 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The COVID-19 outbreak and resulted national lockdown imposed by the Government of India has caused Pan-India disruption of business. The company has considered the possible risk that may result from the pandemic on the carrying amount of its financial and non-financial assets, for which the Company has used the principles of prudence in applying judgments and assumptions as well as the internal / external information available up to the date of approval of these results and the same does not have material impact on these financial results. The Company will continue to closely monitor any material impact of future economic conditions.
- The total sale for the quarter ended 31.03.2021 includes sale of Products of Rs. 548.34 Lakhs the demand for which arose due to Covid 19 Pandemic.**
- The standalone audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- During the year, the company paid Rs. 10.92 Lakhs towards corporate social responsibility (CSR) expenditure.
- The Board of Directors of the company has recommended a dividend of Rs. 1.50 per equity share for the financial year ended on 31st March, 2021. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.

For and on behalf of Board of Directors  
For TITAN BIOTECH LIMITED

**NARESH KUMAR SINGLA**  
Managing Director

DIN-00027448

Place : Delhi

Dated : 29.06.2021



**TITAN BIOTECH LIMITED**  
**Standalone Balance Sheet as at 31st March, 2021**

(Rs. in Lakhs.)

Particulars	As at	
	31/03/2021 Audited	31/03/2020 Audited
<b>I ASSETS</b>		
<b>1. Non-Current Assets</b>		
a. Property, Plant and Equipment	2,497.62	2,462.89
b. Right of use Assets	196.94	50.91
c. Capital Work-in-Progress	27.05	-
d. Intangible assets	9.17	10.09
e. Financial Assets		
(i) Investments	127.50	127.50
(ii) Other Financial Assets	745.19	57.62
<b>Total Non-current assets</b>	<b>3,603.47</b>	<b>2,709.01</b>
<b>2. Current Assets</b>		
a. Inventories	2,682.82	2,414.03
b. Financial Assets		
(i) Trade receivables	1,611.72	1,053.92
(ii) Cash and cash equivalents	530.86	170.10
(iii) Bank balances other than (ii) above	18.39	2.46
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	169.75	170.34
<b>Total Current assets</b>	<b>5,013.54</b>	<b>3,810.85</b>
<b>TOTAL ASSETS</b>	<b>8,617.01</b>	<b>6,519.86</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>A Equity</b>		
a. Equity Share Capital	826.37	826.37
b. Other Equity	5,755.64	2,954.97
<b>TOTAL EQUITY</b>	<b>6,582.01</b>	<b>3,781.34</b>
<b>B Liabilities</b>		
<b>1. Non-Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	182.68	847.82
(ii) Lease liabilities	139.83	
b. Deferred tax liabilities (Net)	134.83	119.67
c. Provisions	141.13	123.91
<b>Total Non-Current Liabilities</b>	<b>598.47</b>	<b>1,091.40</b>
<b>2. Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	570.89	840.97
(ii) Lease liabilities	25.02	
(iii) Trade payables	268.47	357.03
(iv) Other financial liabilities	430.24	283.14
b. Other current liabilities	133.82	127.01
c. Current Tax Liabilities (Net)	8.09	38.97
<b>Total Current Liabilities</b>	<b>1,436.53</b>	<b>1,647.12</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>8,617.01</b>	<b>6,519.86</b>

For and on behalf of Board of Directors  
For TITAN BIOTECH LIMITED



 

NARESH KUMAR SINGLA  
Managing Director

Place : Delhi

Date : 29.06.2021

DIN-00027448

<b>TITAN BIOTECH LIMITED</b> <b>Standalone Cash Flow Statement for the period ended 31st March, 2021</b> <b>(Rs. in Lakhs.)</b>		
Particulars	Year ended	Year ended
	31/03/2021 Audited	31/03/2020 Audited
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before Tax	3,876.15	824.25
<b>Adjustment for :</b>	-	-
Finance Costs	127.54	190.09
Provisions	25.30	21.72
Earlier year Taxes	(1.02)	
Depreciation and Amortization Expenses	210.41	174.52
Operating profit before working capital changes	4,238.38	1,210.58
Changes in working Capital:		
Inventories	(268.79)	(418.02)
Trade and other Receivables	(1,244.78)	(189.16)
Trade and other Payables	65.34	242.78
Cash generation from Operation	2,790.13	846.18
Payment of Direct Taxes	(1,015.62)	(153.86)
<b>Net Cash generated/ (used) - Operating Activities</b>	<b>1,774.51</b>	<b>692.32</b>
<b>B. CASH FLOW FROM INVESTMENT ACTIVITIES</b>		
Purchase of Fixed Assets (incl.Capital WIP)	(271.26)	(57.09)
Right of use assets	(146.03)	(50.91)
Movement in Fixed Deposits with Banks	(15.93)	13.67
<b>Net Cash Generated/ (Used) - Investing Activities</b>	<b>(433.22)</b>	<b>(94.33)</b>
<b>C.CASH FLOW FROM FINANCING ACTIVITIES</b>		
Repayment of Long-term Borrowings	(665.13)	(353.79)
Repayment of Lease Liabilities	164.85	
Proceeds/(Repayment) of Short-term Borrowings (Net)	(270.07)	(42.81)
Finance Cost paid	(127.54)	(190.09)
Dividend paid	(82.64)	-
<b>Net Cash Generated/ (Used) - Financing Activities</b>	<b>(980.53)</b>	<b>(586.69)</b>
<b>Net Increase/ (Decrease) in Cash and Cash Equivalents</b>	<b>360.76</b>	<b>11.30</b>
Add : Opening Cash and Cash Equivalents	170.10	158.80
<b>Closing Cash and Cash Equivalents (refer note-8)</b>	<b>530.86</b>	<b>170.10</b>
<b>Notes:</b> 1. The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7). 2. Figures in bracket represent outflows. 3. Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.		
<div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div> Place : Delhi  Date : 29.06.2021 </div> <div style="text-align: right;"> For and on behalf of Board of Directors  <b>For TITAN BIOTECH LIMITED</b>      <b>NARESH KUMAR SINGLA</b>  Managing Director    <b>DIN-00027448</b> </div> </div>		



**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A, RICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2021**

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED				
		QUARTER ENDED			YEAR ENDED	
		31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
		AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED
1	<b>INCOME</b>					
	Revenue from operations	3,556.52	3,459.71	2,007.84	14,223.72	7,943.80
	Other Income	25.30	13.63	18.18	78.84	44.95
	<b>Total Income</b>	<b>3,581.82</b>	<b>3,473.34</b>	<b>2,026.02</b>	<b>14,302.56</b>	<b>7,988.75</b>
2	<b>EXPENSES</b>					
	Cost of Materials Consumed	2,008.80	1,578.44	954.67	6,730.24	4,025.12
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(119.25)	100.73	(38.30)	(273.41)	(89.24)
	Employee Benefit Expenses	423.89	357.28	348.85	1,405.23	1,247.49
	Finance Costs	49.36	33.72	61.20	166.76	233.58
	Depreciation and Amortization Expenses	83.92	46.23	44.95	221.73	180.02
	Other Expenses	515.40	446.20	426.15	1,749.01	1,412.77
	<b>Total Expenses</b>	<b>2,962.12</b>	<b>2,562.60</b>	<b>1,797.52</b>	<b>9,999.56</b>	<b>7,009.74</b>
3	Profit/(loss) before exceptional items and tax (1-2)	619.70	910.74	228.50	4,303.00	979.01
4	Exceptional Items	(41.44)	-	0.00	(32.44)	61.41
5	Profit/ (loss) before tax (3+4)	578.26	910.74	228.50	4,270.56	1,040.42
6	Tax expense:					
	I) Current Tax	174.91	222.43	39.12	1,085.57	239.38
	II) Earlier year taxes	(0.99)	0.29	(2.39)	0.56	(2.39)
	III) Deferred Tax	(4.41)	6.48	(3.19)	13.90	19.69
	<b>Total Tax (I+II)</b>	<b>169.51</b>	<b>229.20</b>	<b>33.54</b>	<b>1,100.03</b>	<b>256.68</b>
7	Profit (Loss) for the period after Tax (5-6)	<b>408.75</b>	<b>681.54</b>	<b>194.95</b>	<b>3,170.53</b>	<b>783.74</b>
8	<b>other comprehensive income (Net of Tax)</b>					
A.	Items that will not be reclassified to profit or loss			-		
	Re-measurement gain on defined benefit plans	5.21	-	(5.02)	5.21	(5.02)
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total Other Comprehensive Income for the period (A+B)(net of taxes)</b>	<b>5.21</b>	<b>-</b>	<b>(5.02)</b>	<b>5.21</b>	<b>(5.02)</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>413.96</b>	<b>681.54</b>	<b>189.93</b>	<b>3,175.74</b>	<b>778.72</b>
10	<b>Net profit attributable to:</b>					
	Owners of the holding company	376.11	662.48	192.47	3,033.52	706.58
	Non-controlling interest	32.64	19.06	2.49	137.01	77.16
11	<b>Other comprehensive income attributable to :</b>					
	Owners of the holding company	5.60	-	(4.88)	5.60	(4.88)
	Non-controlling interest	(0.39)	-	(0.14)	(0.39)	(0.14)
12	<b>Total Comprehensive Income attributable to (10+11)</b>					
	Owners of the holding company	381.71	662.48	187.59	3,039.12	701.70
	Non-controlling interest	32.25	19.06	2.35	136.62	77.02
13	<b>Paid-up equity share capital (Face Value of Rs. 10/- each)</b>	<b>826.37</b>	<b>826.37</b>	<b>826.37</b>	<b>826.37</b>	<b>826.37</b>
14	<b>Other Equity</b>				<b>6,049.45</b>	<b>3,092.96</b>
15	<b>Earnings per equity share (face value of Rs.10/- each) not annualised</b>					
	(1) Basic	4.55	8.02	2.33	36.71	8.55
	(2) Diluted	4.55	8.02	2.33	36.71	8.55

**Notes:**

- The above consolidated audited financial results for the quarter and year ended on 31.03.2021 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on June 29, 2021. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The consolidated audited financial results for the quarter and year ended on 31.03.2021 include the results of following:-  
Subsidiary Company - Peptech Biosciences Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31 March 2021 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The COVID-19 outbreak and resulted national lockdown imposed by the Government of India has caused Pan-India disruption of business. The company has considered the possible risk that may result from the pandemic on the carrying amount of its financial and non-financial assets, for which the Company has used the principles of prudence in applying judgments and assumptions as well as the internal / external information available up to the date of approval of these results and the same does not have material impact on these financial results. The Company will continue to closely monitor any material impact of future economic conditions.
- The total sale for the quarter ended on 31.03.2021 includes sale of Products of Rs. 548.34 Lakhs the demand for which arose due to Covid 19 Pandemic.**
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- During the year, the company paid Rs. 10.92 Lakhs towards corporate social responsibility (CSR) expenditure.
- The Board of Directors of the company has recommended a dividend of Rs. 1.50 per equity share for the financial year ended on 31st March, 2021. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.

For and on behalf of Board of Directors

For TITAN BIOTECH LIMITED

**NARESH KUMAR SINGLA**  
Managing Director

Place : Delhi  
Dated : 29.06.2021

DIN-00027448

**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2021**

(Rs. IN LAKHS) except for EPS

S.NO.	PARTICULARS	CONSOLIDATED				
		QUARTER ENDED			YEAR ENDED	
		31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
		AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED
1	Total Income from Operations (Net)	3,581.82	3,473.34	2,026.02	14,302.56	7,988.75
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	619.70	910.74	228.50	4,303.00	979.01
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	578.26	910.74	228.50	4,270.56	1,040.42
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	408.75	681.54	194.95	3,170.53	783.74
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	413.96	681.54	189.93	3,175.74	778.72
6	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet			-	6,049.45	3,092.96
8	Earning Per Share (of INR 10/- each)					
	(a) Basic	4.55	8.02	2.33	36.71	8.55
	(b) Diluted	4.55	8.02	2.33	36.71	8.55

**NOTES :**

- The above is an extract of the detailed format of consolidated audited Financial Results for the quarter and year ended on 31.03.2021 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter and year ended on 31st March, 2021 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated audited financial results for the quarter and year ended on 31.03.2021 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on June 29, 2021. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31st March, 2021 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The COVID-19 outbreak and resulted national lockdown imposed by the Government of India has caused Pan-India disruption of business. The company has considered the possible risk that may result from the pandemic on the carrying amount of its financial and non-financial assets, for which the Company has used the principles of prudence in applying judgments and assumptions as well as the internal / external information available up to the date of approval of these results and the same does not have material impact on these financial results. The Company will continue to closely monitor any material impact of future economic conditions.
- The total sale for the quarter ended on 31.03.2021 includes sale of Products of Rs. 548.34 Lakhs the demand for which arose due to Covid 19 Pandemic.**
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- During the year, the company paid Rs. 10.92 Lakhs towards corporate social responsibility (CSR) expenditure.
- The Board of Directors of the company has recommended a dividend of Rs. 1.50 per equity share for the financial year ended on 31st March, 2021. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.

For and on behalf of Board of Directors  
For TITAN BIOTECH LIMITED





**NARESH KUMAR SINGLA**  
Managing Director

**DIN-00027448**



Place : Delhi  
Dated : 29.06.2021

**TITAN BIOTECH LIMITED**  
**Consolidated Balance Sheet as at 31st March, 2021**

(Rs. in Lakhs.)

Particulars	As at	
	31/03/2021 Audited	31/03/2020 Audited
<b>I ASSETS</b>		
<b>1. Non-Current Assets</b>		
a. Property, Plant and Equipment	2,620.91	2,561.07
b. Right of use Assets	730.59	545.18
c. Capital Work-in-Progress	27.05	6.60
d. Intangible assets	9.17	10.09
e. Financial Assets		
(i) Other Financial Assets	750.95	60.93
f. Other Non Current Assets	-	0.30
<b>Total Non-current assets</b>	<b>4,138.67</b>	<b>3,184.17</b>
<b>2. Current Assets</b>		
a. Inventories	3,253.77	2,797.58
b. Financial Assets	-	-
(i) Trade receivables	1,810.38	1,186.25
(ii) Cash and cash equivalents	545.06	183.27
(iii) Bank balances other than (ii) above	18.39	2.46
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	305.29	250.23
<b>Total Current assets</b>	<b>5,932.89</b>	<b>4,419.79</b>
<b>TOTAL ASSETS</b>	<b>10,071.56</b>	<b>7,603.96</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>A Equity</b>		
a. Equity Share Capital	826.37	826.37
b. Other Equity	6,049.44	3,092.96
c. Non Controlling Interest	371.79	235.17
<b>TOTAL EQUITY</b>	<b>7,247.60</b>	<b>4,154.50</b>
<b>B Liabilities</b>		
<b>1. Non-Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	485.53	1,155.38
(ii) Lease liabilities	139.83	
b. Deferred tax liabilities (Net)	138.92	123.27
c. Provisions	148.72	127.83
<b>Total Non-Current Liabilities</b>	<b>913.00</b>	<b>1,406.48</b>
<b>2. Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	828.53	1,134.05
(ii) Lease liabilities	25.02	
(iii) Trade payables	371.35	412.39
(iv) Other Financial Liabilities	500.35	322.99
b. Other current liabilities	150.01	135.05
c. Current Tax Liabilities (Net)	35.70	38.50
<b>Total Current Liabilities</b>	<b>1,910.96</b>	<b>2,042.98</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>10,071.56</b>	<b>7,603.96</b>
<div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div> Place : Delhi  Date : 29.06.2021 </div> <div style="text-align: center;"> For and on behalf of Board of Directors  For TITAN BIOTECH LIMITED      <b>NARESH KUMAR SINGLA</b>  Managing Director  DIN-00027448 </div> </div>		



<b>TITAN BIOTECH LIMITED</b> <b>Consolidated Cash Flow Statement for the period ended 31st March, 2021</b> (Rs. in Lakhs.)		
Particulars	Period ended	Year ended
	31/03/2021 Audited	31/03/2020 Audited
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before Tax	4,270.56	1,040.42
Adjustment for :	-	-
Finance Costs	166.76	233.58
MAT Credit	-	2.65
Earlier year Taxes	(0.56)	(0.26)
Provision for employees Benefits	27.85	23.55
Depreciation and Amortization Expenses	221.73	180.02
Unamortized Expenses	0.30	0.30
Operating profit before working capital changes	4,686.64	1,480.26
Changes in working Capital:		
Inventories	(456.20)	(684.26)
Trade and other Receivables	(1,369.22)	(243.78)
Trade and other Payables	151.29	278.11
Cash generation from Operation	3,012.51	830.33
Payment of Direct Taxes	(1,088.37)	(218.69)
<b>Net Cash generated/ (used) - Operating Activities</b>	1,924.14	611.64
<b>B. CASH FLOW FROM INVESTMENT ACTIVITIES</b>		
Purchase of Fixed Assets (incl.Capital WIP and Right of use assets)	(301.08)	(401.14)
Right of use assets	(185.41)	-
Proceeds/ Repayment of Loans to Body Corporate (Net)	(305.53)	166.43
Movement in Fixed Deposits with Banks	(15.93)	13.67
<b>Net Cash Generated/ (Used) - Investing Activities</b>	(807.95)	(221.04)
<b>C.CASH FLOW FROM FINANCING ACTIVITIES</b>		
Repayment of Long-term Borrowings	(669.85)	(161.23)
Repayment of Lease Liabilities	164.85	-
Finance Cost paid	(166.76)	(233.58)
Dividend paid	(82.64)	-
<b>Net Cash Generated/ (Used) - Financing Activities</b>	(754.40)	(394.81)
<b>Net Increase/ (Decrease) in Cash and Cash Equivalents</b>	361.79	(4.21)
Add : Opening Cash and Cash Equivalents	183.27	187.48
<b>Closing Cash and Cash Equivalents</b>	<b>545.06</b>	<b>183.27</b>
<b>Notes:</b>		
1. The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7). . 2. Figures in bracket represent outflows. 3. Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.		
<div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div> Place : Delhi  Date : 29.06.2021 </div> <div style="text-align: center;"> For and on behalf of Board of Directors  For TITAN BIOTECH LIMITED      <b>NARESH KUMAR SINGLA</b>  Managing Director  DIN-00027448 </div> </div>		



# TITAN BIOTECH LTD.



AN ISO 9001:2015 CERTIFIED COMPANY

Corporate Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subash Place, Delhi-110034, India

Tel. : 011-27355742, 71239900 | CIN: L74999RJ1992PLC013387


**Titan Biotech Limited**


**DISCLOSURE IN ACCORDANCE WITH REGULATION 52(4) OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.**

- A. credit rating and change in credit rating (if any): N/A
- B. asset cover available, in case of non-convertible debt securities: N/A
- C. Debt-equity ratio: 0.13
- D. previous due date for the payment of interest/ dividend for non-convertible redeemable preference shares/ repayment of principal of non-convertible preference shares /non-convertible debt securities and whether the same has been paid or not; and N/A
- E. next due date for the payment of interest/ dividend of non-convertible preference shares /principal along with the amount of interest/ dividend of non-convertible preference shares payable and the redemption amount; N/A
- F. Debt service coverage ratio:4.93
- G. Interest service coverage ratio:33.30
- H. Outstanding redeemable preference shares (quantity and value):NIL
- I. Capital redemption reserve/debenture redemption reserve: NIL
- J. Net worth: Rs.65,82,01,133.84
- K. Net profit after tax: Rs.28,77,26,706.47
- L. Earnings per share:34.82

Dated: 29.06.2021  
Place: Delhi

For Titan Biotech limited

  
Charanjit Singh  
(Company Secretary)

  
Prem Shankar Gupta  
(Chief Financial Officer)

**R.O. & Works:** Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan  
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan  
**E-mail:** marketing@titanbiotechltd.com